Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells

Eisenreich,Andreas; Zakrzewicz,Andreas; Huber,Kilian; Thierbach,Hannes; Pepke,Wojciech; Goldin-Lang,Petra; Schultheiss,Heinz-Peter; Pries,Axel; Rauch,Ursula

doi:10.3892/or.2013.2413

Regulation of pro-angiogenic tissue factor expression in hypoxia-induced human lung cancer cells

Authors:
- Andreas Eisenreich
- Andreas Zakrzewicz
- Kilian Huber
- Hannes Thierbach
- Wojciech Pepke
- Petra Goldin-Lang
- Heinz-Peter Schultheiss
- Axel Pries
- Ursula Rauch
View Affiliations

Affiliations: Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Centrum für Herz- und Kreislaufmedizin, D-12200 Berlin, Germany, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Institute of Physiology, D-14195 Berlin, Germany, CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria
Published online on: April 22, 2013 https://doi.org/10.3892/or.2013.2413
Pages: 462-470

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alternative splicing is a key regulatory mechanism for cellular metabolism controlling cell proliferation and angiogenesis, both of which are crucial processes for tumorigenesis under hypoxia. Human cells express two tissue factor (TF) isoforms, alternatively spliced TF (asTF) and ‘full length’ TF (flTF). flTF is the major source of thrombogenicity whereas, the function of soluble asTF, particularly in cancer, is widely unknown. In the present study, we examined the impact of alternative splicing on the pro-angiogenic potential and the TF expression pattern of A549 cells under hypoxia. We focused our efforts toward alternative splicing factors, such as Clk1, and pro-angiogenic proliferation-regulating factors, such as Cyr61. We further examined the influence of asTF overexpression on the expression of MCP-1, Cyr61 and VEGF, as well as on cell number and pro-angiogenic properties of A549 cells. Notably, we found hypoxia to induce the expression of alternative splicing factors (Clk1 and Clk4) as well as proliferation- and angiogenesis-promoting factors (Cyr61 and flTF). asTF overexpression in A549 cells also increased both cell number and tube formation. These effects were mediated by the induction of Cyr61, MCP-1 and VEGF, as well as by integrin αvβ3. Taken together, our results suggest that the pro-angiogenic potential of A549 lung cancer cells is modulated under hypoxic conditions via modulation of TF isoform expression which in turn is controlled by alternative splicing.

View Figures

View References

1	Eisenreich A, Celebi O, Goldin-Lang P, Schultheiss HP and Rauch U: Upregulation of tissue factor expression and thrombogenic activity in human aortic smooth muscle cells by irradiation, rapamycin and paclitaxel. Int Immunopharmacol. 8:307–311. 2008. View Article : Google Scholar : PubMed/NCBI
2	Giesen PL, Rauch U, Bohrman B, et al: Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA. 96:2311–2315. 1999. View Article : Google Scholar : PubMed/NCBI
3	Rauch U, Antoniak S, Boots M, et al: Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol. 6:2542005. View Article : Google Scholar : PubMed/NCBI
4	Szotowski B, Antoniak S, Poller W, Schultheiss HP and Rauch U: Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res. 96:1233–1239. 2005. View Article : Google Scholar : PubMed/NCBI
5	Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M and Nemerson Y: Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med. 9:458–462. 2003. View Article : Google Scholar : PubMed/NCBI
6	Eisenreich A, Bogdanov VY, Zakrzewicz A, et al: Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res. 104:589–599. 2009. View Article : Google Scholar : PubMed/NCBI
7	Eisenreich A, Malz R, Pepke W, Ayral Y, Poller W, Schultheiss HP and Rauch U: Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells. Circ J. 73:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tardos JG, Eisenreich A, Deikus G, et al: SR proteins ASF/SF2 and SRp55 participate in tissue factor biosynthesis in human monocytic cells. J Thromb Haemost. 6:877–884. 2008. View Article : Google Scholar : PubMed/NCBI
9	Rauch U and Antoniak S: Tissue factor-positive microparticles in blood associated with coagulopathy in cancer. Thromb Haemost. 97:9–10. 2007.PubMed/NCBI
10	Eisenreich A, Boltzen U, Malz R, Schultheiss HP and Rauch U: Overexpression of alternatively spliced tissue factor induces the pro-angiogenic properties of murine cardiomyocytic HL-1 cells. Circ J. 75:1235–1242. 2011. View Article : Google Scholar : PubMed/NCBI
11	Eisenreich A and Rauch U: Regulation and differential role of the tissue factor isoforms in cardiovascular biology. Trends Cardiovasc Med. 20:199–203. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hobbs JE, Zakarija A, Cundiff DL, et al: Alternatively spliced human tissue factor promotes tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res. 120(Suppl 2): S13–S21. 2007. View Article : Google Scholar : PubMed/NCBI
13	van den Berg YW, van den Hengel LG, Myers HR, et al: Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA. 106:19497–19502. 2009.PubMed/NCBI
14	Goldin-Lang P, Tran QV, Fichtner I, et al: Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep. 20:123–128. 2008.
15	Zhang T, Koide N, Wada Y, et al: Significance of monocyte chemotactic protein-1 and thymidine phosphorylase in angiogenesis of human cardiac myxoma. Circ J. 67:54–60. 2003. View Article : Google Scholar : PubMed/NCBI
16	Zhang Y, Han J, Yang X, et al: Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. Oncol Rep. 26:681–686. 2011.PubMed/NCBI
17	Shimizu T, Okayama A, Inoue T and Takeda K: Analysis of gene expression during staurosporine-induced neuronal differentiation of human prostate cancer cells. Oncol Rep. 14:441–448. 2005.PubMed/NCBI
18	Chen N, Leu SJ, Todorovic V, Lam SC and Lau LF: Identification of a novel integrin α_vβ₃ binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem. 279:44166–44176. 2004.
19	Hutchings H, Ortega N and Plouët J: Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J. 17:1520–1522. 2003.
20	Löbel M, Bauer S, Meisel C, et al: CCN1: CCN1: a novel inflammation-regulated biphasic immune cell migration modulator. Cell Mol Life Sci. 69:3101–3113. 2012.PubMed/NCBI
21	Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM and Ruf W: Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood. 116:6106–6113. 2010. View Article : Google Scholar : PubMed/NCBI
22	Fedorov O, Huber K, Eisenreich A, et al: Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 18:67–76. 2011. View Article : Google Scholar : PubMed/NCBI
23	Schwertz H, Tolley ND, Foulks JM, et al: Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med. 203:2433–2440. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kim SH, Kim KW and Jeong JW: Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1α suppression. Oncol Rep. 17:793–797. 2007.PubMed/NCBI
25	Łuczak MW, Roszak A, Pawlik P, Kędzia H, Lianeri M and Jagodziński PP: Increased expression of HIF-1A and its implication in the hypoxia pathway in primary advanced uterine cervical carcinoma. Oncol Rep. 26:1259–1264. 2011.PubMed/NCBI
26	Gang H, Hai Y, Dhingra R, et al: A novel hypoxia-inducible spliced variant of mitochondrial death gene Bnip3 promotes survival of ventricular myocytes. Circ Res. 108:1084–1092. 2011. View Article : Google Scholar : PubMed/NCBI
27	Hirschfeld M, zur Hausen A, Bettendorf H, Jäger M and Stickeler E: Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res. 69:2082–2090. 2009. View Article : Google Scholar : PubMed/NCBI
28	Tazi J, Bakkour N and Stamm S: Alternative splicing and disease. Biochim Biophys Acta. 1792:14–26. 2009. View Article : Google Scholar : PubMed/NCBI
29	Xu F, Shi J, Yu B, Ni W, Wu X and Gu Z: Chemokines mediate mesenchymal stem cell migration toward gliomas in vitro. Oncol Rep. 23:1561–1567. 2010.PubMed/NCBI
30	Zhao X, Li DC, Zhao H, et al: A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression. Oncol Rep. 27:628–636. 2012.PubMed/NCBI
31	Arderiu G, Peña E, Aledo R, Juan-Babot O and Badimon L: Tissue factor regulates microvessel formation and stabilization by induction of chemokine (C-C motif) ligand 2 expression. Arterioscler Thromb Vasc Biol. 31:2607–2615. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ollivier V, Bentolila S, Chabbat J, Hakim J and de Prost D: Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood. 91:2698–2703. 1998.PubMed/NCBI
33	Roberts JR, Perkins GD, Fujisawa T, Pettigrew KA, Gao F, Ahmed A and Trickett DR: Vascular endothelial growth factor promotes physical wound repair and is anti-apoptotic in primary distal lung epithelial and A549 cells. Crit Care Med. 35:2164–2170. 2007. View Article : Google Scholar : PubMed/NCBI
34	Loges S, Butzal M, Otten J, et al: Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Biochem Biophys Res Commun. 357:1016–1020. 2007. View Article : Google Scholar : PubMed/NCBI
35	Cirillo P, Calì G, Golino P, et al: Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation. 109:2911–2916. 2004. View Article : Google Scholar : PubMed/NCBI
36	Bourgeois CF, Lejeune F and Stévenin J: Broad specificity of SR (serine/arginine) proteins in the regulation of alternative splicing of pre-messenger RNA. Prog Nucleic Acids Res Mol Biol. 78:37–88. 2004. View Article : Google Scholar : PubMed/NCBI
37	Eisenreich A, Boltzen U, Poller W, Schultheiss HP and Rauch U: Effects of the Cdc2-like kinase-family and DNA topoisomerase I on the alternative splicing of eNOS in TNF-α-stimulated human endothelial cells. Biol Chem. 389:1333–1338. 2008.PubMed/NCBI
38	Eisenreich A and Rauch U: PI3K inhibitors in cardiovascular disease. Cardiovasc Ther. 29:29–36. 2011. View Article : Google Scholar
39	Prasad J, Colwill K, Pawson T and Manley JL: The protein kinase Clk/Sty directly modulates SR protein activity: both hyper- and hypophosphorylation inhibit splicing. Mol Cell Biol. 19:6991–7000. 1999.PubMed/NCBI